ViiV HEALTHCARE LAUNCHES “THE UNSTOPPABLES” TO CELEBRATE LEADERS ACROSS THE HIV COMMUNITY WHO ARE DRIVING PROGRESS TO END THE EPIDEMIC
- New campaign recognises innovators, advocates and community pioneers across HIV, with the first of The Unstoppables unveiled today
- Hosted by media partner VICE, The Unstoppables share their personal journeys of breaking through barriers and driving life-changing innovation across the global HIV community
London, 12 August 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today launched The Unstoppables, a new campaign created in partnership with VICE that spotlights the pioneers advancing society towards a future free from HIV. The campaign recognises innovation in all its forms; the scientists, advocates, community leaders and educators whose work is transforming HIV prevention, treatment and care for all people affected by HIV.
Built around the knowledge that ending the HIV epidemic requires dedication and collaboration across the community, the campaign spotlights just some of the voices, representative of the many contributions that together are breaking down barriers and driving progress. From next generation scientific breakthroughs to grassroots activism and innovative approaches to education, The Unstoppables celebrates some of the people at the forefront of progress in HIV.
Professor Linda-Gail Bekker, Director of the Desmond Tutu HIV Centre at the University of Cape Town and former President of the International AIDS Society, commented: "Moving the needle in the HIV response has always taken a village, but the battle is far from over. We need new pioneers to continue to pass the baton, as it’s vital we maintain our momentum. Campaigns like The Unstoppables are incredibly important to not only recognise the incredible work but also inspire and encourage the next generation of researchers, advocates, and activists. I believe in Ubuntu—the idea that we must look out for one another. If we can fuel the fire in the bellies of young leaders today to keep up the pressure, we will ultimately succeed."
Today, ViiV Healthcare celebrates the work of the first Unstoppable in the series, Marty St. Clair. Marty St. Clair is a pioneering scientist who has helped shape major advances in HIV treatment, her work playing an important role in expanding what is possible for people living with HIV from the discovery of the first antiretroviral treatment (ART) through to innovative long-acting options.
The Unstoppables featured in the campaign embody the passion, diversity and relentless drive at the heart of the HIV response. Watch the campaign video and discover the first stories from The Unstoppables here: https://www.vice.com/theunstoppables.
“The HIV response has always been defined by the courage to challenge convention, the persistence to overcome barriers and the innovation to transform lives - principles that drive what we do at ViiV,” said Audrey Abernathy, Head of Communications, Patient Engagement and Government Affairs, ViiV Healthcare. “We’re proud to launch The Unstoppables with VICE to recognise some of the extraordinary people across the HIV community whose work has had, and continues to have, a significant impact on our shared ambition to end the HIV epidemic.”
Adam Stimpson, Global VP, Commercial at VICE added: “This is exactly what we're here for — putting a spotlight on the people at the frontline of the HIV response who are doing work that deserves to be seen. The HIV epidemic is one of the most pressing global health priorities of our time, and we're proud to use this platform to tell these stories.”
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.
About VICE
VICE is an award-winning global media brand covering culture, music, fashion, technology, food, identity and the ideas shaping contemporary life. Through fearless journalism, original storytelling and a distinct editorial voice, VICE explores the people, trends and issues defining culture around the world. Alongside its digital platforms, VICE publishes a quarterly print magazine featuring long-form reporting, photography and original creative work.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
| ViiV Healthcare enquiries: | |||
| Media: | Kate Senter | +44 (0) 77 9670 7446 | (London) |
| Melinda Stubbee | +1 919 491 0831 | (North Carolina) | |
| GSK enquiries: | |||
| Media: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
| Sarah Clements | +44 (0) 20 8047 5502 |
(London) | |
| Kathleen Quinn | +1 202 603 5003 | (Washington DC) | |
| Alison Hunt | +1 540 742 3391 | (Washington DC) | |
| Investor Relations: | Constantin Fest | +44 (0) 7831 826525 | (London) |
| Joanna Tuplin | +44 (0) 7788 351650 | (London) | |
| James Dodwell | +44 (0) 7881 269066 | (London) | |
| Mick Readey | +44 (0) 7990 339653 | (London) | |
| Sam Piper | +44 (0) 7824 525779 | (London) | |
| Dan Smith | +44 (0) 7823 523885 | (London) | |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) | |
| Frannie DeFranco | +1 215 751 3126 | (Philadelphia) | |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q2 Results for 2026.
Registered in England & Wales:
GSK plc ViiV Healthcare Limited
No. 3888792 No. 06876960
Registered Office:
79 New Oxford Street ViiV Healthcare Limited
London GSK Medicines Research Centre
WC1A 1DG Gunnels Wood Road, Stevenage
United Kingdom
SG1 2NY
Media contacts
For our corporate press office, email: Kate Senter
OR call +44 7796 707446
For US-specific media enquiries, email: Rachel Jaikaran
OR call +1 9193578932
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
